Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amneal PharmaceuticalsAMRX +2.12%59 10-Year Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus rates AMRX with a GF Score™ of 59/100 and a GF Value™ of $8.19 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 623 Drug Manufacturers companies, Amneal Pharmaceuticals ranks worse than 160513.48% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Amneal Pharmaceuticals's current 10-Year Share Buyback Ratio was 0.00%.
AMRX's 10-Year Share Buyback Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: -2.1 * Ranked among companies with meaningful 10-Year Share Buyback Ratio only.
Amneal Pharmaceuticals (NAS:AMRX) 10-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Amneal Pharmaceuticals 10-Year Share Buyback Ratio Related Terms
AMRX vs KNSA, LQDA, LNTH: 10-Year Share Buyback Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amneal Pharmaceuticals 10-Year Share Buyback Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's 10-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Amneal Pharmaceuticals's 10-Year Share Buyback Ratio falls into.
Amneal Pharmaceuticals 10-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 10-Year Share Buyback Ratio of 0.00 mean?
Amneal Pharmaceuticals (AMRX) has a 10-Year Share Buyback Ratio of 0.00 as of Jun. 2026. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Amneal Pharmaceuticals and its competitors. According to the industry distribution chart, Amneal Pharmaceuticals ranks #999999 out of 623 companies in the Drug Manufacturers industry.
Is Amneal Pharmaceuticals' 10-Year Share Buyback Ratio too high?
Amneal Pharmaceuticals' current 10-Year Share Buyback Ratio is 0.00. Based on the distribution chart, Amneal Pharmaceuticals ranks #999999 out of 623 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Amneal Pharmaceuticals has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' 10-Year Share Buyback Ratio compare to KNSA and LQDA?
According to the Drug Manufacturers industry distribution chart, Amneal Pharmaceuticals ranks #999999 out of 623 companies for 10-Year Share Buyback Ratio. This places Amneal Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year Share Buyback Ratio for a Drug Manufacturers company?
A good 10-Year Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 10-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year Share Buyback Ratio mean?
A high 10-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Amneal Pharmaceuticals and its competitors. Amneal Pharmaceuticals's current 10-Year Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (AMRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $8.19, compared to a current price of $18.07 — trading 120.6% above its estimated fair value. The current 10-Year Share Buyback Ratio is 0.00. Amneal Pharmaceuticals' overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year Share Buyback Ratio calculated?
10-Year Share Buyback Ratio is calculated from a company's financial statements. For Amneal Pharmaceuticals (AMRX), the current 10-Year Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?
Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued.
The current stock price of $18.07 is trading 120.6% above its estimated GF Value™ of $8.19.
GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for AMRX:
10-Year Share Buyback Ratio: 0.00
GF Value™: $8.19 vs. price of $18.07 (120.6% above fair value)
No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
59GF Score
Get the complete analysis for AMRX
10-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMRX has been successfully added to your 
